Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study.
chemotherapy
immune checkpoint inhibitors
immune-monitoring
malignant melanoma
salvage therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
11
2019
accepted:
15
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
Melanoma survival increased with targeted- and immunotherapy agents, yet most patients ultimately progress and require salvage therapy. In our experience, some progressive disease patients on immune-checkpoint inhibitors (ICIs) demonstrate deep and sustained responses to chemotherapy. We hypothesized that ICIs improve the response to subsequent chemotherapy in metastatic melanoma. We conducted a retrospective study to compare the efficacy of chemotherapy given with prior immunotherapy, to its efficacy given without it. We measured progression free survival (PFS), overall survival, and response rate. Immune-monitoring was performed on sequential peripheral blood mononuclear cell samples taken from a chemotherapy-responsive patient. The chemotherapy post-immunotherapy group (CpI) included 11 patients, the chemotherapy without prior immunotherapy (CNPI) group included 24 patients. Median PFS was 5.2 months in the CpI vs. 2.5 months in the CNPI groups; HR 0.37 [95% Confidence interval (CI) 0.144-0.983],
Identifiants
pubmed: 32117727
doi: 10.3389/fonc.2020.00070
pmc: PMC7033746
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70Informations de copyright
Copyright © 2020 Hadash-Bengad, Hajaj, Klein, Merims, Frank, Eisenberg, Yakobson, Orevi, Caplan, Peretz, Lotem and Cohen.
Références
Immunology. 2002 Jun;106(2):127-38
pubmed: 12047742
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
Eur J Cancer. 2019 Nov;121:123-129
pubmed: 31574417
Clin Dermatol. 2013 May-Jun;31(3):290-7
pubmed: 23608448
Invest New Drugs. 2011 Jun;29(3):489-98
pubmed: 20082117
Adv Immunol. 2016;130:251-77
pubmed: 26923003
Oncotarget. 2017 Aug 8;8(53):91795-91802
pubmed: 29207685
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Acta Oncol. 2019 Mar;58(3):379-381
pubmed: 30614355
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
J Immunother. 2016 Oct;39(8):321-8
pubmed: 27564312
Curr Oncol. 2008 Apr;15(2):85-9
pubmed: 18454183
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Eur J Cancer. 1972 Feb;8(1):85-92
pubmed: 4552317
Cytometry. 1997 Jan 1;27(1):71-6
pubmed: 9000587
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Ann Oncol. 2017 Oct 1;28(10):2581-2587
pubmed: 28961848
J Thorac Oncol. 2018 Jan;13(1):106-111
pubmed: 29101058
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Eur J Cancer. 2004 Aug;40(12):1825-36
pubmed: 15288283
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Lung Cancer. 2017 Oct;112:90-95
pubmed: 29191606
Mol Oncol. 2014 Sep 12;8(6):1132-9
pubmed: 25106088